# US 10,500,267 B2 · Influenza virus vectors and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,267 B2
- Document ID: US10500267B2
- Status: Granted
- Kind: B2
- Application number: 15/681,613
- Filed: 2017-08-21
- Published: 2018-02-15
- Granted: 2019-12-10
- Earliest claimed: 2014-03-17
- Assignees: FluGen, Inc.
- Applicants: FluGen, Inc.
- Inventors: Matthew Frederick LeFebvre; Yasuko Hatta; Pamuk Bilsel; Michael J. Moser
- Web page: https://patentgrep.com/patent/US10500267B2

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/575: {humoral response}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16143: viral genome or elements thereof as genetic vector
- C12N 2760/16152: relating to complementing cells and packaging systems for producing virus or viral particles
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.

## Claims

### Claim 1

An immunogenic composition comprising the nucleic acid sequence of SEQ ID NO:35, wherein SEQ ID NO:35 further comprises a nucleic acid sequence encoding one or more foreign antigens.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, further comprising part or all of SEQ ID NO:36.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the one or more foreign antigens comprises an amino acid sequence derived from a pathogen or a tumor.

### Claim 4 (depends on 3)

The immunogenic composition of claim 3, wherein the pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.

### Claim 5 (depends on 1)

A method for propagating a recombinant influenza virus, comprising: contacting a host cell with a recombinant influenza virus comprising the nucleic acid sequence of claim 1, incubating the host cell for a sufficient time and under conditions suitable for viral replication, and isolating progeny virus particles.

### Claim 6 (depends on 5)

The method of claim 5, wherein the recombinant influenza virus further comprises part or all of SEQ ID NO:36.

### Claim 7 (depends on 5)

The method of claim 5, wherein the one or more foreign antigens comprises an amino acid sequence derived from a pathogen or a tumor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.

### Claim 9 (depends on 1)

A method of preparing a vaccine, comprising: placing a host cell in a bioreactor; contacting the host cell with a recombinant virus comprising the nucleic acid sequence of claim 1, incubating the host cell for a sufficient time and under conditions suitable for viral propagation; isolating the progeny virus particles; and formulating the progeny virus particles for administration as a vaccine.

### Claim 10 (depends on 9)

The method of claim 9, wherein the nucleic acid sequence further comprises part or all of SEQ ID NO: 36.

### Claim 11 (depends on 9)

The method of claim 9, wherein the one or more foreign antigens comprises an amino acid sequence derived from a pathogen or a tumor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.